These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36151869)

  • 1. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
    Joseph-Mathurin N; Llibre-Guerra JJ; Li Y; McCullough AA; Hofmann C; Wojtowicz J; Park E; Wang G; Preboske GM; Wang Q; Gordon BA; Chen CD; Flores S; Aggarwal NT; Berman SB; Bird TD; Black SE; Borowski B; Brooks WS; Chhatwal JP; Clarnette R; Cruchaga C; Fagan AM; Farlow M; Fox NC; Gauthier S; Hassenstab J; Hobbs DA; Holdridge KC; Honig LS; Hornbeck RC; Hsiung GR; Jack CR; Jimenez-Velazquez IZ; Jucker M; Klein G; Levin J; Mancini M; Masellis M; McKay NS; Mummery CJ; Ringman JM; Shimada H; Snider BJ; Suzuki K; Wallon D; Xiong C; Yaari R; McDade E; Perrin RJ; Bateman RJ; Salloway SP; Benzinger TLS; Clifford DB;
    Ann Neurol; 2022 Nov; 92(5):729-744. PubMed ID: 36151869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
    Wagemann O; Liu H; Wang G; Shi X; Bittner T; Scelsi MA; Farlow MR; Clifford DB; Supnet-Bell C; Santacruz AM; Aschenbrenner AJ; Hassenstab JJ; Benzinger TLS; Gordon BA; Coalier KA; Cruchaga C; Ibanez L; Perrin RJ; Xiong C; Li Y; Morris JC; Lah JJ; Berman SB; Roberson ED; van Dyck CH; Galasko D; Gauthier S; Hsiung GR; Brooks WS; Pariente J; Mummery CJ; Day GS; Ringman JM; Mendez PC; St George-Hyslop P; Fox NC; Suzuki K; Okhravi HR; Chhatwal J; Levin J; Jucker M; Sims JR; Holdridge KC; Proctor NK; Yaari R; Andersen SW; Mancini M; Llibre-Guerra J; Bateman RJ; McDade E;
    JAMA Neurol; 2024 Jun; 81(6):582-593. PubMed ID: 38683602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Salloway S; Farlow M; McDade E; Clifford DB; Wang G; Llibre-Guerra JJ; Hitchcock JM; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Cruchaga C; Goate AA; Perrin RJ; Xiong C; Li Y; Morris JC; Snider BJ; Mummery C; Surti GM; Hannequin D; Wallon D; Berman SB; Lah JJ; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sánchez-Valle R; Brooks WS; Gauthier S; Galasko DR; Masters CL; Brosch JR; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Jack CR; Koeppe R; Snyder PJ; Aisen PS; Thomas RG; Berry SM; Wendelberger BA; Andersen SW; Holdridge KC; Mintun MA; Yaari R; Sims JR; Baudler M; Delmar P; Doody RS; Fontoura P; Giacobino C; Kerchner GA; Bateman RJ;
    Nat Med; 2021 Jul; 27(7):1187-1196. PubMed ID: 34155411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
    N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
    Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
    Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Wang G; Li Y; Xiong C; McDade E; Clifford DB; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Libre-Guerra JJ; McCullough A; Joseph-Mathurin N; Chen CD; Mummery C; Wendelberger BA; Gauthier S; Masellis M; Holdridge KC; Yaari R; Chatterjee S; Sims J; Delmar P; Kerchner GA; Bittner T; Hofmann C; Bateman RJ;
    Alzheimers Dement (Amst); 2022; 14(1):e12367. PubMed ID: 36348972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
    Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
    J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
    Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
    Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
    Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of Solanezumab in Preclinical Alzheimer's Disease.
    Sperling RA; Donohue MC; Raman R; Rafii MS; Johnson K; Masters CL; van Dyck CH; Iwatsubo T; Marshall GA; Yaari R; Mancini M; Holdridge KC; Case M; Sims JR; Aisen PS;
    N Engl J Med; 2023 Sep; 389(12):1096-1107. PubMed ID: 37458272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
    Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
    Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.
    Wang G; Li Y; Xiong C; Benzinger TLS; Gordon BA; Hassenstab J; Aschenbrenner AJ; McDade E; Clifford DB; Libre-Guerra JJ; Shi X; Mummery CJ; van Dyck CH; Lah JJ; Honig LS; Day G; Ringman JM; Brooks WS; Fox NC; Suzuki K; Levin J; Jucker M; Delmar P; Bittner T; Bateman RJ;
    Alzheimers Dement; 2024 Apr; 20(4):2698-2706. PubMed ID: 38400532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal head-to-head comparison of
    Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.
    Retout S; Gieschke R; Serafin D; Weber C; Frey N; Hofmann C
    Clin Pharmacol Ther; 2022 Apr; 111(4):857-866. PubMed ID: 35100444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
    Loomis SJ; Miller R; Castrillo-Viguera C; Umans K; Cheng W; O'Gorman J; Hughes R; Budd Haeberlein S; Whelan CD
    Neurology; 2024 Feb; 102(3):e207919. PubMed ID: 38165296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.
    Liu H; Li J; Ziegemeier E; Adams S; McDade E; Clifford DB; Cao Y; Wang G; Li Y; Mills SL; Santacruz AM; Belyew S; Grill JD; Snider BJ; Mummery CJ; Surti G; Hannequin D; Wallon D; Berman SB; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sanchez-Valle R; Brooks WS; Gauthier S; Galasko D; Masters CL; Brosch J; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Bateman RJ; Llibre-Guerra JJ
    J Prev Alzheimers Dis; 2024; 11(3):558-566. PubMed ID: 38706272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.
    Carlson C; Siemers E; Hake A; Case M; Hayduk R; Suhy J; Oh J; Barakos J
    Alzheimers Dement (Amst); 2016; 2():75-85. PubMed ID: 27239538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.